Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | PHASE1 | RECRUITING | 81 | — | — | Mar 8, 2022 | Dec 1, 2025 | Nov 3, 2025 | 1 | Taiwan |
Number and incidence of (serious) adverse events (AEs) (\[S\]AEs), including rate of mild, moderate, and severe hypersensitivity reactions, fluid retention, and sensory neuropathy an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle.
| Arm | Type | Description |
|---|---|---|
| MPB-1734, single arm, dose escalation | EXPERIMENTAL | intravenous, once per 3 weeks, starting at 10 mg/m˄2 |
| Name | Type | Description |
|---|---|---|
| MPB-1734 | DRUG | Administered once daily in a 21-day cycle |
Inclusion Criteria: 1. Signed informed consent in the local language prior to any study-mandated procedure. 2. Male or female patients at least 18 years of age, at the time of informed consent. 3. Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid t...